In: In vivo CAR-T
Trials
2 active
2 in total
Targets
—
None known yet
What this is
- How it works
- Reprograms the patient's own immune T cells, inside the body, to hunt one kind of cell, such as cancerous B cells. Standard CAR-T does this in a lab.In vivo CAR-T, target not disclosed
- How it’s given
- “Patients were enrolled and given a single dose of CAR-T injection intravenously, hospitalized for observation over the following month, and followed up for observation over the following 2 years.”In the company’s words, NCT07239323 on ClinicalTrials.gov
- Tested for
- B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, Relapsed or Refractory Multiple Myeloma (RRMM)
- Main trialPhase 1
- “This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory malignant hematological tumors. It is an early exploratory clinical study of the safety, tolerability and initial efficacy in the treatment of relapsed or refractory malignant hematological tumors.”In the company’s words, NCT07239323 on ClinicalTrials.gov
- Other names
- Invivo CAR-T (unconfirmed)
Coming up2
- 31 Dec 2027Phase 1 trial completes · ClinicalTrials.gov
- 30 Apr 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 31 Dec 2027 | In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies | |
| Phase 1Recruiting | 30 Apr 2028 | In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 16 Nov 2026 · EU trials register (CTIS) updated 16 Nov 2026 · openFDA updated 13 Nov 2026